URGN logo

UroGen Pharma (URGN) Cash From Financing

Annual CFF

$194.62 M
+$77.69 M+66.44%

December 31, 2024

Summary

Performance

1-Year Change

+66.44%

3-Year Change

+169.11%

5-Year Change

+17.77%

15-Year Change

+216.02%

URGN Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

90.95%
URGN annual cash flow from financing activities is higher than 90.95% of companies in Healthcare sector

High & Low

All-time High

$194.62 M
URGN annual cash flow from financing activities is currently at an all-time high

3-Year Low

$72.32 M
URGN annual cash flow from financing activities is currently +169.11% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
URGN previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
URGN next annual earnings announcement has not yet been scheduled

OtherURGNcash flowmetrics:

Annual CFI

-$20.61 M
URGN annual cash flow from investing activities is -$20.61 million

Annual CFO

-$96.77 M
URGN annual cash flow from operations is -$96.77 million

Annual FCF

-$97.06 M
URGN annual free cash flow is -$97.06 million

Annual CAPEX

$295.00 K
URGN annual capital expenditures is $295.00 thousand

Quarterly CFF

$71.00 K
-$39.53 M-99.82%

December 1, 2024

Summary

Performance

3-Month Change

-99.82%

1-Year Change

-99.82%

3-Year Change

+321.88%

5-Year Change

-71.02%

URGN Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

49.65%
URGN quarterly cash flow from financing activities is higher than 49.65% of companies in Healthcare sector

High & Low

All-time High

$163.51 M
URGN quarterly cash flow from financing activities is currently -99.96% below its historical high of $163.51 million

3-Year Low

-$77.00 K

Earnings dates

Last Quarterly Earnings Report Date

Dec 1, 2024
URGN previous earnings announcement was published on Dec 1, 2024

Next Quarterly Earnings Report Date

May 13, 2025
URGN next earnings announcement is scheduled for May 13, 2025

OtherURGNcash flowmetrics:

Quarterly CFI

$60.62 M
URGN quarterly cash flow from investing activities is $60.62 million

Quarterly CFO

-$13.62 M
URGN quarterly cash flow from operations is -$13.62 million

Quarterly FCF

-$13.73 M
URGN quarterly free cash flow is -$13.73 million

Quarterly CAPEX

$115.00 K
URGN quarterly capital expenditures is $115.00 thousand

TTM CFF

$194.62 M
+$31.00 K+0.02%

December 1, 2024

Summary

Performance

3-Month Change

+0.02%

1-Year Change

+0.02%

3-Year Change

+169.11%

5-Year Change

+17.77%

URGN TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89.05%
URGN TTM cash flow from financing activities is higher than 89.05% of companies in Healthcare sector

High & Low

All-time High

$271.06 M
URGN TTM cash flow from financing activities is currently -28.20% below its historical high of $271.06 million

3-Year Low

$27.06 M
URGN TTM cash flow from financing activities is currently +619.13% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 1, 2024
URGN previous earnings announcement was published on Dec 1, 2024

Next Quarterly Earnings Report Date

May 13, 2025
URGN next earnings announcement is scheduled for May 13, 2025

OtherURGNcash flowmetrics:

TTM CFI

-$20.61 M
URGN TTM cash flow from investing activities is -$20.61 million

TTM CFO

-$96.77 M
URGN TTM cash flow from operations is -$96.77 million

TTM FCF

-$97.06 M
URGN TTM free cash flow is -$97.06 million

TTM CAPEX

$295.00 K
URGN TTM capital expenditures is $295.00 thousand

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

URGN Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+66.4%-99.8%+0.0%
3 y3 years+169.1%+321.9%+169.1%
5 y5 years+17.8%-71.0%+17.8%

URGN Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+169.1%-99.9%+192.2%-28.2%+619.1%
5 y5-yearat high+1077.6%-99.9%+142.3%-28.2%>+9999.0%
alltimeall timeat high>+9999.0%-100.0%+117.8%-28.2%>+9999.0%

UroGen Pharma Cash From Financing History

DateAnnualQuarterlyTTM
Dec 2024
$194.62 M(+66.4%)
-
-
Dec 2024
-
$71.00 K(-99.8%)
$194.62 M(+0.0%)
Sep 2024
-
$39.61 M(-60.5%)
$194.59 M(-28.2%)
Jun 2024
-
$100.28 M(+83.5%)
$271.06 M(+58.6%)
Mar 2024
-
$54.66 M(>+9900.0%)
$170.92 M(+46.2%)
Dec 2023
$116.93 M(+20.4%)
$40.00 K(-100.0%)
$116.93 M(-17.8%)
Sep 2023
-
$116.08 M(>+9900.0%)
$142.26 M(+421.4%)
Jun 2023
-
$143.00 K(-78.7%)
$27.28 M(+0.8%)
Mar 2023
-
$671.00 K(-97.4%)
$27.06 M(-72.1%)
Dec 2022
$97.13 M(+34.3%)
$25.37 M(+2204.1%)
$97.13 M(+35.4%)
Sep 2022
-
$1.10 M(-1529.9%)
$71.73 M(+1.8%)
Jun 2022
-
-$77.00 K(-100.1%)
$70.47 M(-50.7%)
Mar 2022
-
$70.74 M(<-9900.0%)
$143.06 M(+97.8%)
Dec 2021
$72.32 M(+337.6%)
-$32.00 K(-81.0%)
$72.32 M(-0.2%)
Sep 2021
-
-$168.00 K(-100.2%)
$72.43 M(-0.3%)
Jun 2021
-
$72.52 M(>+9900.0%)
$72.66 M(+341.9%)
Mar 2021
-
$4000.00(-94.9%)
$16.44 M(-0.5%)
DateAnnualQuarterlyTTM
Dec 2020
$16.53 M(-90.0%)
$78.00 K(+27.9%)
$16.53 M(-1.0%)
Sep 2020
-
$61.00 K(-99.6%)
$16.69 M(-6.0%)
Jun 2020
-
$16.30 M(>+9900.0%)
$17.76 M(+868.3%)
Mar 2020
-
$90.00 K(-63.3%)
$1.83 M(-98.9%)
Dec 2019
$165.25 M(+148.8%)
$245.00 K(-78.2%)
$165.25 M(-1.2%)
Sep 2019
-
$1.13 M(+201.9%)
$167.21 M(+0.7%)
Jun 2019
-
$373.00 K(-99.8%)
$166.06 M(+0.2%)
Mar 2019
-
$163.51 M(+7332.1%)
$165.67 M(+149.4%)
Dec 2018
$66.42 M(+7.9%)
$2.20 M(<-9900.0%)
$66.42 M(+3.5%)
Sep 2018
-
-$14.00 K(-33.3%)
$64.17 M(+0.6%)
Jun 2018
-
-$21.00 K(-100.0%)
$63.78 M(-49.4%)
Mar 2018
-
$64.26 M(<-9900.0%)
$125.95 M(+104.5%)
Dec 2017
$61.59 M(<-9900.0%)
-$56.00 K(-86.0%)
$61.59 M(-0.1%)
Sep 2017
-
-$399.00 K(-100.6%)
$61.64 M(-0.6%)
Jun 2017
-
$62.15 M(<-9900.0%)
$62.04 M(<-9900.0%)
Mar 2017
-
-$108.00 K
-$108.00 K
Dec 2016
-$9000.00(-100.0%)
-
-
Dec 2015
$21.58 M
-
-

FAQ

  • What is UroGen Pharma annual cash flow from financing activities?
  • What is the all time high annual CFF for UroGen Pharma?
  • What is UroGen Pharma annual CFF year-on-year change?
  • What is UroGen Pharma quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for UroGen Pharma?
  • What is UroGen Pharma quarterly CFF year-on-year change?
  • What is UroGen Pharma TTM cash flow from financing activities?
  • What is the all time high TTM CFF for UroGen Pharma?
  • What is UroGen Pharma TTM CFF year-on-year change?

What is UroGen Pharma annual cash flow from financing activities?

The current annual CFF of URGN is $194.62 M

What is the all time high annual CFF for UroGen Pharma?

UroGen Pharma all-time high annual cash flow from financing activities is $194.62 M

What is UroGen Pharma annual CFF year-on-year change?

Over the past year, URGN annual cash flow from financing activities has changed by +$77.69 M (+66.44%)

What is UroGen Pharma quarterly cash flow from financing activities?

The current quarterly CFF of URGN is $71.00 K

What is the all time high quarterly CFF for UroGen Pharma?

UroGen Pharma all-time high quarterly cash flow from financing activities is $163.51 M

What is UroGen Pharma quarterly CFF year-on-year change?

Over the past year, URGN quarterly cash flow from financing activities has changed by -$39.53 M (-99.82%)

What is UroGen Pharma TTM cash flow from financing activities?

The current TTM CFF of URGN is $194.62 M

What is the all time high TTM CFF for UroGen Pharma?

UroGen Pharma all-time high TTM cash flow from financing activities is $271.06 M

What is UroGen Pharma TTM CFF year-on-year change?

Over the past year, URGN TTM cash flow from financing activities has changed by +$31.00 K (+0.02%)